Syncona (SYNC.L)
A London-listed investment firm that creates and builds pioneering life science companies, with a specialized focus on advanced therapies and oncology.
What Syncona does
Syncona is a London-listed healthcare investment company focused on founding, building, and funding life science companies. It primarily invests in the development of innovative treatments, with a core focus on gene therapy, cell therapy, and oncology.
Themes: biotechnology venture capital, gene therapy, cell therapy, oncology innovation, life sciences investment
Fundamentals
- Price£1.07 as of 2026-08-03 close
- Market capn/a company fundamentals are not available for UK-listed companies in our data
- 1-year return+10.7% 2025-08-01 close £0.965 → 2026-08-03 close £1.07
- P/En/a company fundamentals are not available for UK-listed companies in our data
- Net marginn/a company fundamentals are not available for UK-listed companies in our data
- Gross marginn/a company fundamentals are not available for UK-listed companies in our data
- ROEn/a company fundamentals are not available for UK-listed companies in our data
- Debt / equityn/a company fundamentals are not available for UK-listed companies in our data
- Revenue growth (YoY)n/a company fundamentals are not available for UK-listed companies in our data
- Revenue CAGR (3y)n/a company fundamentals are not available for UK-listed companies in our data
- Betan/a we do not track a market benchmark for UK-listed companies
Dividend: company fundamentals are not available for UK-listed companies in our data.
How Syncona looks technically
Syncona (SYNC.L) is trading 9.6% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 22 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 32, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 22 trading days ago. It is 2.7% below its 52-week high (its highest price of the past year). Trading volume is unusually light — only about 0% of its 30-day average.
Trend
| Distance from the 200-day | +9.6% | it is trading 9.6% above its 200-day average, the long-term trend line — a longer-term uptrend |
|---|---|---|
| 50-day moving average | £1.03 | its average price over the last 50 trading days — a short-term trend line — is £1.03 |
| 200-day moving average | £0.9741 | its average price over the last 200 trading days — the long-term trend line — is £0.9741 |
| Since the 50/200 cross | 22 sessions | its 50-day average crossed above its 200-day average about 22 trading days ago — a "golden cross", a bullish long-term signal |
| Above the 200-day after a dip | +9.6% | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 9.6% above |
| Trend strength (14-day ADX) | 31.8 | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 32, with sellers in control |
Momentum
| 14-day RSI | 55.2 | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30) |
|---|---|---|
| Since the MACD crossed zero | 14 sessions | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) |
Range
| 52-week high | £1.10 | its highest closing price over the past year (about 252 trading days) was £1.10 |
|---|---|---|
| From the 52-week high | -2.7% | it is 2.7% below its 52-week high (its highest price of the past year) |
| Above the 52-week low | +23.0% | it is 23.0% above its 52-week low (its lowest price of the past year) |
| Below the 52-week high | 2.7% | it is 2.7% below its highest point of the past year |
| Since a 20-day breakout | 22 sessions | it made a new 20-day high about 22 trading days ago |
| Since a 55-day breakout | 22 sessions | it made a new 55-day high about 22 trading days ago |
| All-time high | £3.06 | its highest closing price on record is £3.06 (set on 2018-10-03) |
| From the all-time high | -65.2% | it is 65.2% below its all-time high |
| All-time low | £0.007983 | its lowest closing price on record is £0.007983 (set on 2025-06-05) |
| Above the all-time low | +13,278% | it is 13278.4% above its all-time low |
Volatility
| Band width vs its own 6 months | 14th percentile | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 86% of it) |
|---|---|---|
| Bollinger bands (20-day, ±2σ) | £1.05 – £1.07 – £1.09 | most of its recent trading has stayed between about £1.05 and £1.09 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles |
Volume
| Volume vs its 30-day average | 0.00× | trading volume is unusually light — only about 0% of its 30-day average |
|---|
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · Near the 52-week high | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-03. Describes past price behavior only — informational, not financial advice.
Key risks (from latest filing)
["high-risk nature of early-stage biotechnology investments","significant capital requirements and long development timelines for clinical-stage assets","volatility in the public equity markets impacting investment valuations"]
Competitors & peers
- Blackstone Life Sciences (BX)
- Abingworth
- Atlas Venture
- Sofinnova Partners
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare SYNC.L vs…
Frequently asked questions
What does Syncona (SYNC.L) do?
Syncona is a London-listed healthcare investment company focused on founding, building, and funding life science companies. It primarily invests in the development of innovative treatments, with a core focus on gene therapy, cell therapy, and oncology.
Who are Syncona's (SYNC.L) competitors?
Notable peers of Syncona (SYNC.L) include Blackstone Life Sciences, Abingworth, Atlas Venture and Sofinnova Partners. This peer set is informational only — not financial advice.
Is Syncona (SYNC.L) overbought or oversold right now?
Syncona (SYNC.L) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 55, in the neutral middle (as of 2026-08-03). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on SYNC.L come from?
Fundamentals and prices come from market data. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data. Prices are delayed daily-close data.
Last updated 2026-08-03.
Informational only — NOT financial advice. All figures are delayed daily-close data from market data, shown with their as-of date.